10 results about "Phosphatidylinositol" patented technology

This invention provides the application of phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)) in the identification of Hainan camellia, relating to the field of food testing technology. The phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)) can be used as a characteristic marker for the identification of Hainan camellia. This invention is the first to discover that the kernels of Hainan camellia contain high levels of phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)), while phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)) is not found or present in extremely low amounts in the kernels of other camellia species besides Hainan camellia. Phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)) can be used to identify and distinguish Hainan camellia from other camellia species. Furthermore, this identification method is simple to operate and achieves rapid, objective, and accurate identification of Hainan camellia.

The application discloses a method for regulating virus proliferation in rice planthopper. The method regulates the content of 3,5-bisphospho phosphatidylinositol (PI(3,5)P2) to regulate the proliferation of rice black-streaked dwarf virus in the body of Laodelphax striatellus and southern rice black-streaked dwarf virus in the body of white-backed planthopper. The PI(3,5)P2 inhibitor or dsRNA of PI(3,5)P2 synthesis enzyme gene PIKfyve is applied by microinjection, drop or spraying to reduce the content of PI(3,5)P2 in the body of Laodelphax striatellus and white-backed planthopper, thereby inhibiting the proliferation of rice black-streaked dwarf virus in the body of Laodelphax striatellus and southern rice black-streaked dwarf virus in the body of white-backed planthopper. The PI(3,5)P2 homolog PI(3,5)P2-diC8 is applied to Laodelphax striatellus to increase the content of PI(3,5)P2, thereby promoting the proliferation of rice black-streaked dwarf virus in the body of Laodelphax striatellus. The application provides a new method for controlling virus diseases transmitted by vector insects.

This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.

The strain BS-14 can convert the nutrients in the solid culture into nutrients absorbed and utilized by the bacillus subtilis, and the microenvironment generated by the fermentation of the strain BS-14 is also beneficial to promote the fermentation of MQ013-26, so that the enzyme activity concentration of the natto kinase is further improved. The strain BS-14 can further decompose phospholipid substances (phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol) and fat, so that the spoilage odor of the freeze-dried powder can be further improved, and the shelf life can be prolonged. The strain BS-14 can further generate active peptides against pathogenic microorganisms, and has significant bacteriostatic activity, so that the quality safety of the freeze-dried powder is improved.

This invention relates to a drug for treating ischemia-reperfusion injury and its application. The drug activates the CCL2-chemokine receptor 2 signaling axis, triggering the downstream G protein αi2 subunit-mediated phosphatidylinositol 3-kinase / protein kinase B signaling pathway. This, in turn, synergistically regulates the antioxidant defense system driven by nuclear factor erythroid 2-related factor 2 and the B-cell lymphoma 2-mediated anti-apoptotic pathway, thereby treating the ischemia-reperfusion injury. The results of this study establish a novel therapeutic strategy for testicular ischemia-reperfusion injury based on engineered exosomes, and simultaneously reveal the previously undiscovered cytoprotective role of the CCL2 / CCR2 signaling axis in non-immune cells.

This invention belongs to the field of pharmaceutical technology and relates to thienopyrimidine derivatives, their preparation methods, uses, and pharmaceutical compositions. The thienopyrimidine derivatives, as shown in formula (I), are phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors and can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, kidney diseases, cardiovascular diseases, inflammation, metabolic / endocrine dysfunction, or neurological diseases.

This disclosure provides compounds of Formula (I), Formula (I-I), and Formula (I-II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These compounds are useful for treating a disease in which increased PI3Kα activation contributes to the pathology, symptoms, and / or progression of the disease (e.g., cancer) in a subject.

This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα) for use in combination with additional therapeutic agents for treating a condition, disease or disorder in which increased (e.g., excessive) PI3Kα activation contributes to the pathology and / or symptoms and / or progression of the condition, disease or disorder (e.g., cancer) in a subject.

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: (I) or a pharmaceutically acceptable salt there- of, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor, wherein the compound of Formula I or pharmaceutically ac- ceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

This invention discloses a *Acer truncatum* seed oil-PS composite composition that promotes nerve development, belonging to the field of food nutrition technology. The composite composition comprises the following components by weight: 8-12 parts *Acer truncatum* seed oil, 3-6 parts phosphatidylserine, 1-2 parts phospholipids, 2-4 parts flaxseed oil, 0.5-2 parts arachidonic acid phosphatidylinositol, 1-3 parts docosahexaenoic acid phospholipids, 0.3-1.5 parts sialic acid, 0.2-1 parts phytosterols, 0.1-0.8 parts d-α-tocopherol, 0.5-2 parts emulsifier, and 0.05-0.3 parts antioxidant synergist. This invention scientifically combines multiple nutritional components to form a synergistic system, meeting the nutritional needs of nerve development, providing comprehensive nutritional support, and significantly enhancing the promotion effect. Simultaneously, it constructs a brain-targeting lipid-phospholipid hybrid nanocarrier, combined with refined processing, to improve the targeting and bioavailability of the composition, retaining biological activity, and possessing good storage properties and safety for use, facilitating widespread application.